During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the prescription drug marketplace. Women’s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women.
Scope and Methodology
For this study, the worldwide prescription drug market for women’s health is discussed in total manufacturers’ revenues for the following product categories:
- Autoimmune diseases
- Gynecological and Sexually Transmitted Diseases
- Urinary Disorders
The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 62 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.
All market data are presented at the manufacturers’ level in current U.S dollars. The base year for data was 2002. Historical data are provided for each of the years 1997 through 2002, and forecast data are provided for each of the years 2003 through 2007. Historical, base year, and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2002 base year.